NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.56
▼ -0.06 (-1.30%)

This chart shows the closing price for MACK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merrimack Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MACK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MACK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Merrimack Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.56.

This chart shows the closing price for MACK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Merrimack Pharmaceuticals. This rating has held steady since November 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2018CowenReiterated RatingHoldMedium
10/20/2018Robert W. BairdSet Price TargetNeutral ➝ Hold$7.00 ➝ $4.00High
10/19/2018CowenReiterated RatingHoldHigh
6/26/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$12.00 ➝ $7.00High
6/25/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
3/15/2018Robert W. BairdReiterated RatingHold$12.00Low
10/13/2017Robert W. BairdReiterated RatingHold$15.00N/A
5/19/2017CowenReiterated RatingMarket PerformLow
1/24/2017CowenReiterated RatingMarket PerformN/A
1/12/2017CowenReiterated RatingMarket PerformN/A
1/11/2017Robert W. BairdReiterated RatingNeutral$50.00N/A
12/23/2016Robert W. BairdReiterated RatingNeutral$70.00N/A
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$70.00N/A
11/10/2016BTIG ResearchReiterated RatingNeutralN/A
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Merrimack Pharmaceuticals logo
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.56
Low: $4.37
High: $4.61

50 Day Range

MA: $4.67
Low: $4.30
High: $5.16

52 Week Range

Now: $4.56
Low: $3.56
High: $9.45

Volume

31,492 shs

Average Volume

48,574 shs

Market Capitalization

$61.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Merrimack Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Merrimack Pharmaceuticals in the last twelve months:
View the latest analyst ratings for MACK.

What is the current price target for Merrimack Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Merrimack Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Merrimack Pharmaceuticals in the next year.
View the latest price targets for MACK.

What is the current consensus analyst rating for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MACK.

What other companies compete with Merrimack Pharmaceuticals?

How do I contact Merrimack Pharmaceuticals' investor relations team?

Merrimack Pharmaceuticals' physical mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for Merrimack Pharmaceuticals is www.merrimackpharma.com.